Biotech · Public company · Austin, TX, US
Genprex, Inc.
Ticker GNPX · SEC CIK 0001595248
Track this companyFree. Adds Genprex, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline14
- atezolizumabPhase 2 · Small Cell Lung Cancer Extensive StageClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 2 · Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- DiphenhydraminePhase 2 · Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- DOTAP:Chol-TUSC2Phase 2 · Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- ErlotinibPhase 2 · Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- osimertinibPhase 2 · Carcinoma, Non-Small Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- Platinum-Based ChemotherapyPhase 2 · Carcinoma, Non-Small Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- quaratusugene ozeplasmidPhase 2 · Carcinoma, Non-Small Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- quaratusugene ozeplasmidPhase 2 · Small Cell Lung Cancer Extensive StageClinicalTrials.gov · fetched Nov 12, 2026
- docetaxelPhase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Investigator's Treatment of ChoicePhase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumabPhase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- quaratusugene ozeplasmidPhase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- ramucirumabPhase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC PatientsPHASE1_PHASE2 · RECRUITING · started May 9, 2024ClinicalTrials.gov NCT05703971 · fetched Nov 12, 2026
- Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung CancerPHASE1 · TERMINATED · started Mar 30, 2022ClinicalTrials.gov NCT05062980 · fetched Nov 12, 2026
- Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibPHASE1_PHASE2 · RECRUITING · started Sep 3, 2021ClinicalTrials.gov NCT04486833 · fetched Nov 12, 2026
- TUSC2-nanoparticles and Erlotinib in Stage IV Lung CancerPHASE1_PHASE2 · TERMINATED · started Feb 1, 2014ClinicalTrials.gov NCT01455389 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 28, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 21, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 18, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 14, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 22, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 18, 2026 · fetched Nov 12, 2026